Meeting on the Mesa: reimbursement prospects should drive cell therapy development
This article was originally published in Clinica
Executive Summary
There are many regenerative medicine companies built around interesting science that tackles chronic diseases or unmet needs, but will payers - both commercial and government health plans - pay for relatively expensive cell therapies?